PL4374878T3 - Kompozycja farmaceutyczna zawierająca karbetocynę - Google Patents

Kompozycja farmaceutyczna zawierająca karbetocynę

Info

Publication number
PL4374878T3
PL4374878T3 PL24166417.6T PL24166417T PL4374878T3 PL 4374878 T3 PL4374878 T3 PL 4374878T3 PL 24166417 T PL24166417 T PL 24166417T PL 4374878 T3 PL4374878 T3 PL 4374878T3
Authority
PL
Poland
Prior art keywords
carbetocin
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
PL24166417.6T
Other languages
English (en)
Inventor
Anders Nilsson
Mattias Malm
Kazimierz Wisniewski
Britta Siekmann
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4374878(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of PL4374878T3 publication Critical patent/PL4374878T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
PL24166417.6T 2010-09-30 2011-09-29 Kompozycja farmaceutyczna zawierająca karbetocynę PL4374878T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10251690 2010-09-30

Publications (1)

Publication Number Publication Date
PL4374878T3 true PL4374878T3 (pl) 2025-06-09

Family

ID=43478408

Family Applications (4)

Application Number Title Priority Date Filing Date
PL17169301T PL3246018T3 (pl) 2010-09-30 2011-09-29 Kompozycja farmaceutyczna
PL17169328T PL3222272T3 (pl) 2010-09-30 2011-09-29 Kompozycje farmaceutyczne karbetocyny
PL11776530T PL2621468T3 (pl) 2010-09-30 2011-09-29 Kompozycja farmaceutyczna karbetocyny
PL24166417.6T PL4374878T3 (pl) 2010-09-30 2011-09-29 Kompozycja farmaceutyczna zawierająca karbetocynę

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL17169301T PL3246018T3 (pl) 2010-09-30 2011-09-29 Kompozycja farmaceutyczna
PL17169328T PL3222272T3 (pl) 2010-09-30 2011-09-29 Kompozycje farmaceutyczne karbetocyny
PL11776530T PL2621468T3 (pl) 2010-09-30 2011-09-29 Kompozycja farmaceutyczna karbetocyny

Country Status (27)

Country Link
US (4) US9566311B2 (pl)
EP (5) EP3246018B1 (pl)
JP (2) JP6038797B2 (pl)
KR (2) KR102102664B1 (pl)
CN (4) CN107080832B (pl)
AU (1) AU2011309762B2 (pl)
BR (2) BR122021001123B1 (pl)
CA (1) CA2812510A1 (pl)
CY (2) CY1119245T1 (pl)
DK (4) DK3246018T3 (pl)
ES (4) ES2905561T3 (pl)
FI (1) FI4374878T3 (pl)
HR (3) HRP20171256T1 (pl)
HU (4) HUE034367T2 (pl)
IL (3) IL225238B (pl)
JO (3) JO3400B1 (pl)
LT (3) LT2621468T (pl)
MX (3) MX352949B (pl)
NZ (1) NZ609719A (pl)
PL (4) PL3246018T3 (pl)
PT (4) PT3246018T (pl)
RS (3) RS66759B1 (pl)
RU (2) RU2737264C2 (pl)
SI (4) SI3246018T1 (pl)
SM (3) SMT202500165T1 (pl)
TW (6) TWI532507B (pl)
WO (1) WO2012042371A2 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
CA2868403A1 (en) * 2012-05-08 2013-11-14 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
FI3666258T3 (fi) * 2014-09-19 2024-02-09 Ferring Bv Menetelmä prader-willin oireyhtymän hoitamiseksi
JP6607509B2 (ja) 2014-10-01 2019-11-20 オキシトーン バイオサイエンス ビー．ブイ． 分娩制御物質を含有する口腔内崩壊性固形医薬投与単位
WO2016053091A1 (en) 2014-10-01 2016-04-07 Oxytone Bioscience B.V. Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance
WO2016112205A1 (en) 2015-01-07 2016-07-14 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
EP4541348A3 (en) 2016-04-12 2025-06-04 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
CN107773531B (zh) * 2016-08-31 2021-05-04 成都倍特药业股份有限公司 一种马来酸麦角新碱注射液
CN108236601B (zh) * 2016-12-23 2020-04-17 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法
WO2019030412A1 (en) * 2017-08-11 2019-02-14 Ferring B.V. PROCESS FOR PRODUCING PHARMACEUTICAL PREPARATION
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
WO2019169342A1 (en) 2018-03-01 2019-09-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
CN112969450B (zh) 2018-09-20 2023-05-30 阿卡蒂亚药品公司 卡贝缩宫素药物产品及用于制备其的方法
CA3112185C (en) * 2018-09-20 2025-10-07 Acadia Pharmaceuticals Inc. STABLE INTRANASAL FORMULATIONS OF CARBETOCINE
CN109745544B (zh) * 2018-11-23 2024-11-08 南京新百药业有限公司 稳定的缩宫素药物组合物及其制备方法
US20220080023A1 (en) * 2018-12-21 2022-03-17 Arecor Limited Novel composition
WO2020137880A1 (ja) * 2018-12-27 2020-07-02 国立大学法人北海道大学 オキシトシン誘導体及びその使用
CA3141488A1 (en) 2019-05-22 2020-11-26 Biovie Inc. Formulations of terlipressin
CN110308222A (zh) * 2019-07-17 2019-10-08 武汉赛沃医药科技有限公司 一种卡贝缩宫素原料药有关物质检测方法
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
JP2023500763A (ja) * 2019-11-04 2023-01-11 フェリング ベスローテン フェンノートシャップ 泌乳の改善のためのメロトシンの鼻腔内投与
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
EP4313106B1 (en) 2021-03-26 2025-01-15 Ot4B Treatment of dysphagia
CN114191388B (zh) * 2021-12-27 2023-06-09 苏州天马医药集团天吉生物制药有限公司 一种卡贝缩宫素制剂的制备方法
CN114712483B (zh) * 2022-05-12 2023-09-29 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途
US12214010B2 (en) 2023-04-04 2025-02-04 Tulex Pharmaceuticals Inc. Desmopressin oral compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1109558A (zh) * 1994-11-07 1995-10-04 马文亮 装有压力表的双管气筒
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
DK1285667T3 (da) 1997-11-18 2006-09-11 Uni Pharma Kleon Tsetis Pharmaceutical Lab Sa Farmaceutisk injicerbar oplösning af paracetamol og kombinationer af paracetamol med andre aktive bestanddele
US6333313B1 (en) 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
US20070032410A1 (en) * 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
JP2001233787A (ja) 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
AU2003279137A1 (en) 2002-10-03 2004-04-23 Neuropharmacology Services, Llc Treatment of autism and similar disorders
JP2006515882A (ja) 2003-01-08 2006-06-08 カイロン コーポレイション 組織因子経路インヒビター（ｔｆｐｉ）または組織因子経路インヒビター改変体を含有する安定化水性組成物
AU2004218369A1 (en) 2003-03-05 2004-09-16 Pr Pharmaceuticals Oxytocin controlled release formulations and methods of using same
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CA2689476C (en) * 2007-06-07 2014-08-05 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism
EP2178386B1 (en) 2007-07-02 2010-11-03 Sime Darby Malaysia Berhad Frying fat composition
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
PT2260053E (pt) * 2008-03-31 2014-08-29 Ferring Bv Análogos de oxitocina
EP2349200A1 (en) * 2008-10-15 2011-08-03 Intarcia Therapeutics, Inc Highly concentrated drug particles, formulations, suspensions and uses thereof

Also Published As

Publication number Publication date
HRP20250382T1 (hr) 2025-05-23
NZ609719A (en) 2014-07-25
RU2737264C2 (ru) 2020-11-26
RS66759B1 (sr) 2025-05-30
KR20180123599A (ko) 2018-11-16
TWI746951B (zh) 2021-11-21
EP3936117A1 (en) 2022-01-12
JOP20180102A1 (ar) 2019-01-30
US20130210746A1 (en) 2013-08-15
TW201940188A (zh) 2019-10-16
KR102102664B1 (ko) 2020-04-22
TW201605465A (zh) 2016-02-16
RU2604690C2 (ru) 2016-12-10
CN107080832B (zh) 2021-05-07
PT4374878T (pt) 2025-05-02
MX390779B (es) 2025-03-21
RS62873B1 (sr) 2022-02-28
DK3246018T3 (da) 2022-01-17
EP2621468A2 (en) 2013-08-07
EP3222272A1 (en) 2017-09-27
ES2637988T3 (es) 2017-10-18
FI4374878T3 (fi) 2025-05-16
HRP20171256T1 (hr) 2017-10-20
TWI750934B (zh) 2021-12-21
RU2016143751A (ru) 2018-12-18
LT4374878T (lt) 2025-04-25
BR112013007362B1 (pt) 2021-05-25
CN103124554A (zh) 2013-05-29
PL2621468T3 (pl) 2017-11-30
CN107080832A (zh) 2017-08-22
SI2621468T1 (sl) 2017-10-30
SI4374878T1 (sl) 2025-06-30
SMT202500165T1 (it) 2025-05-12
MX2013003365A (es) 2013-07-29
TW201729797A (zh) 2017-09-01
EP4374878A2 (en) 2024-05-29
US9566311B2 (en) 2017-02-14
JOP20180103A1 (ar) 2019-01-30
HUE056835T2 (hu) 2022-03-28
HRP20211969T1 (hr) 2022-03-18
LT3222272T (lt) 2021-12-27
AU2011309762B2 (en) 2014-07-17
SMT201700420T1 (it) 2017-11-15
TWI680773B (zh) 2020-01-01
RU2013112666A (ru) 2014-11-10
TWI532507B (zh) 2016-05-11
IL225238A0 (en) 2013-06-27
MX395271B (es) 2025-03-21
TW201605466A (zh) 2016-02-16
JOP20180103B1 (ar) 2022-03-14
HUE070972T2 (hu) 2025-07-28
PT3246018T (pt) 2022-01-13
CA2812510A1 (en) 2012-04-05
JO3400B1 (ar) 2019-10-20
HK1246170A1 (en) 2018-09-07
DK2621468T3 (en) 2017-09-11
PL3246018T3 (pl) 2022-05-02
KR20130136467A (ko) 2013-12-12
CN104906032A (zh) 2015-09-16
WO2012042371A3 (en) 2013-04-04
MX352949B (es) 2017-12-15
CY1119245T1 (el) 2018-02-14
US20170106044A1 (en) 2017-04-20
EP3246018A1 (en) 2017-11-22
BR122021001123B1 (pt) 2021-05-18
SI3246018T1 (sl) 2022-02-28
CY1124924T1 (el) 2023-01-05
EP3246018B1 (en) 2021-11-03
BR112013007362A2 (pt) 2016-07-12
JP2013543492A (ja) 2013-12-05
EP4374878A3 (en) 2024-07-24
PT3222272T (pt) 2022-01-27
TW201219051A (en) 2012-05-16
JOP20180102B1 (ar) 2022-03-14
US20230124105A1 (en) 2023-04-20
IL225238B (en) 2018-07-31
ES3027637T3 (en) 2025-06-16
IL245328B (en) 2022-04-01
US20170106043A1 (en) 2017-04-20
SI3222272T1 (sl) 2022-01-31
JP2017048226A (ja) 2017-03-09
PT2621468T (pt) 2017-09-08
EP2621468B1 (en) 2017-06-14
DK3222272T3 (da) 2022-01-24
HUE057187T2 (hu) 2022-04-28
AU2011309762A1 (en) 2013-04-04
WO2012042371A2 (en) 2012-04-05
JP6038797B2 (ja) 2016-12-07
IL245326B (en) 2021-04-29
SMT202200034T1 (it) 2022-03-21
EP3222272B1 (en) 2021-11-03
JP6250770B2 (ja) 2017-12-20
ES2905561T3 (es) 2022-04-11
EP4374878B1 (en) 2025-02-12
RS56220B1 (sr) 2017-11-30
PL3222272T3 (pl) 2022-03-07
ES2902418T3 (es) 2022-03-28
TW202112389A (zh) 2021-04-01
HUE034367T2 (en) 2018-02-28
IL245328A0 (en) 2016-06-30
TWI661834B (zh) 2019-06-11
IL245326A0 (en) 2016-06-30
DK4374878T3 (da) 2025-05-05
LT2621468T (lt) 2017-11-27
CN107412728A (zh) 2017-12-01
RU2016143751A3 (pl) 2020-01-16
TWI650134B (zh) 2019-02-11
KR101919119B1 (ko) 2018-11-15

Similar Documents

Publication Publication Date Title
IL245328B (en) A pharmaceutical preparation containing carbatocin
PL2619182T3 (pl) Kompozycja farmaceutyczna
IL225457A0 (en) Pharmaceutical composition
HUE031336T2 (hu) Gyógyszerészeti készítmények
PT2579858E (pt) Composição farmacêutica que contém ivabradina
ZA201301920B (en) Pharmaceutical composition
ZA201305591B (en) Fluorocarbon-linked peptide formulation
ZA201302113B (en) Caspofungin composition
GB201010453D0 (en) Pharmaceutical composition
IL226554A (en) Medicinal preparations containing alisporiovir
HUE051133T2 (hu) Gyógyászati készítmények
IL221501A (en) Medicinal product containing miramistine
EP2560678A4 (en) PHARMACEUTICAL COMPOSITIONS
GB201001911D0 (en) Pharmaceutical composition
GB201019775D0 (en) Pharmaceutical composition
HU1000006D0 (en) Improved pharmaceutical composition
GB201008590D0 (en) Pharmaceutical compositions
HUE052801T2 (hu) Gyógyászati készítmények